INM News and Press, InMed Pharmaceuticals Inc. From 06/13/25

Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - InMed Pharmaceuticals Inc.  (NASDAQ: INM)  (" InMed " or the " Company "), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, ...

2025-06-02 10:29:45 ET InMed Pharmaceuticals Inc. (NASDAQ: INM) is one of today’s top gainers. The company’s shares have moved 140.96% on the day to $6. InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based thera...

2025-06-02 09:04:39 ET With Expected Second Quarter 2025 closing, Core Gaming Timing Now at a Crossroads DENVER, Colo., Jun 02, 2025 ( 247marketnews.com )- Siyata Mobile’s (NASDAQ:SYTA) $160 million merger with Core Gaming , though a precise closing date remains under...

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

2025-05-12 18:02:51 ET More on InMed Pharmaceuticals InMed Pharmaceuticals GAAP EPS of -$3.64, revenue of $1.11M Financial information for InMed Pharmaceuticals Read the full article on Seeking Alpha For further details see: InMed Pharmaceuticals Non-GAAP...

Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports fin...

2025-02-13 02:33:43 ET More on InMed Pharmaceuticals Financial information for InMed Pharmaceuticals Read the full article on Seeking Alpha For further details see: InMed Pharmaceuticals GAAP EPS of -$3.64, revenue of $1.11M

Vancouver, British Columbia--(Newsfile Corp. - February 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today report...

Masco Corporation (MAS) is expected to report $0.88 for Q4 2024 Ecolab Inc. (ECL) is expected to report $1.79 for Q4 2024 Krispy Kreme Inc. (DNUT) is expected to report $0.07 for Q4 2024 Navios Maritime Partners LP Representing Limited Partner Interests (NMM) is expected to report $3....

INM-089 IVT formulation selected for continued development Demonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a significant safety margin Dose ranging studies completed Vancouver, British Columbia-...